MANY CANADIAN WOMEN WITH OSTEOPOROSIS AND AT RISK FOR FRACTURE RESTRICTED FROM ACCESS TO A NEW TREATMENT OPTION THAT PREVENTS BROKEN BONES

TORONTO, April 4 /CNW/ - On April 4, 2011, the Canadian Expert Drug Advisory Committee (CEDAC) through the Common Drug Review (CDR) recommended that provincial drug plans approve funding for Prolia® (denosumab), but with some restrictions. Denosumab is a targeted therapy in a new class of osteoporosis medications for postmenopausal women with osteoporosis at high risk for fracture.

"While this recommendation is a positive step forward for some patients, these restrictions are quite limiting and mean that a significant number of postmenopausal women with osteoporosis at high risk for fracture may be left without access to this new treatment, including many women for whom existing therapies are either contraindicated, ineffective or not tolerated," said Dr. Famida Jiwa, President & CEO, Osteoporosis Canada. "Based on these recommendations, Osteoporosis Canada urges provinces to provide broader access to denosumab. Provinces should ensure that this new treatment is accessible to women with osteoporosis that can benefit from treatment for this debilitating disease."

According to the criteria set out by the CDR, denosumab is recommended for women with postmenopausal osteoporosis who would otherwise be eligible for jurisdictional funding for oral bisphosphonates, but for whom bisphosphonates are contraindicated due to hypersensitivity or abnormalities of the esophagus (e.g., esophageal stricture or achalasia), and have at least two of the following: older than 75 years; a prior fragility fracture; bone mineral density (BMD) T-score of ≤-2.5.1 Currently, the most commonly prescribed drugs for this disease are bisphosphonates. Denosumab offers a new effective alternative that is in a completely different class of medications called RANK ligand inhibitors.

Provincial drug plans are not obliged to adhere to the CDR's recommendations as each provincial authority has the right to make listing and coverage decisions based on local priorities and resources. Quebec, for example, has demonstrated leadership by being the first province to list denosumab on public and private drug plans. Even so, patient access to osteoporosis therapies in Canada is limited and varies across the country. In addition, the CDR recommendation is not aligned with Osteoporosis Canada's evidence-based 2010 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada.2

"The 2010 Clinical Practice Guidelines issued by Osteoporosis Canada recommended denosumab as a first-line therapy for the treatment of osteoporosis in postmenopausal women at high risk for fracture," said Dr. Bill Leslie, Chair, Scientific Advisory Council, Osteoporosis Canada. "The CDR recognized in its recommendation that denosumab is clinically effective in reducing the incidence of new hip and vertebral fractures, and is cost-effective in women at high risk of fracture. However, the restrictions on the recommendation will mean that few women at risk will have access to this effective treatment option."

Osteoporosis could strike you or someone you love. It is a silent disease that affects nearly two million Canadians. The risk of a major osteoporotic fracture in Canada is among the highest in the world. Yet, despite the high prevalence of fractures, they are often not appropriately assessed or treated, leaving osteoporosis undiagnosed and undertreated. Broken bones are associated with devastating health consequences including pain, decreased quality of life, loss of independence, and even death. Preventing new fractures for those who have already had an osteoporotic fracture is Osteoporosis Canada's top priority. In 2010, Osteoporosis Canada issued new Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada that help physicians and patients better identify the risk of fracture, resulting in better fracture prevention and better management of osteoporosis overall.

Additional osteoporosis statistics:

  • Almost 2 million Canadians are living with osteoporosis.
  • Over 90% of hip fractures in Canada occur in those over age 60.
  • In the first year after a vertebral or hip fracture there is at least a doubling in the risk of death.
  • Each year in Canada there are about 30,000 hip fractures - many more Canadians suffer osteoporotic fractures affecting the spine, wrist, shoulder, and pelvis.
  • A 50-year-old woman has a 40% chance of developing hip, vertebral or wrist fractures during her lifetime.3
  • Over one-quarter of hip fractures in Canada occur in men.
  • The 1 in 6 lifetime risk of hip fracture is greater than the 1 in 9 lifetime risk of developing breast cancer.4
  • 1 in 4 women who have a new vertebral fracture will fracture again within one year.5

"Osteoporotic fractures can be prevented," said Larry Funnell, Chair, Canadian Osteoporosis Patient Network (COPN). "Patients with osteoporosis deserve to have choices and the right to access the medications they need."

About Osteoporosis Canada
Osteoporosis Canada, a registered charity, is the only national organization serving people who have or are at risk for osteoporosis. In keeping with our vision of a Canada without osteoporotic fractures, the organization works to educate, empower and support individuals and communities in the risk-reduction and treatment of osteoporosis by providing medically accurate information to patients, health professionals and the public. For more information, visit www.osteoporosis.ca.

_______________________________
1 Prolia® Submission Status. Canadian Agency for Drugs and Technology in Health, Common Drug Review. Accessed at http://www.cadth.ca/index.php/en/cdr/search?status=all&order_field=brand_name&keywords=Prolia.
2 Papaioannou A et al. Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2010; 1-10.
3 Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective: how many women have osteoporosis? J Bone Miner Res. 1992; 7:1005-10.
4 Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med. 1989; 149:2445-8.
5 Lindsay R, Burge RT, Strauss DM. One year outcomes and costs following a vertebral fracture. Osteoporosis Int. 2005; 16:78-85.


SOURCE Osteoporosis Canada

For further information:

or to arrange an interview with an Osteoporosis Canada spokesperson, please contact:

Matthew Rocheford
Osteoporosis Canada
(416) 696-2663

Profil de l'entreprise

Osteoporosis Canada

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.